Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study)
Abstract Background In pulmonary arterial hypertension (PAH), comparative assessment of treatment effect on survival in randomized controlled settings of contemporary patients has not been feasible. Objective The aim of this study was to use EXPOSURE, the ongoing, real-world, post-authorization safe...
Saved in:
| Main Authors: | Stefan Söderberg, Pilar Escribano-Subias, Ciara Archey, Audrey Muller, Martina Fontana, Tobias J. Lange, Sean Gaine |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Drugs - Real World Outcomes |
| Online Access: | https://doi.org/10.1007/s40801-025-00488-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
by: N. V. Ilyin, et al.
Published: (2019-12-01) -
Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
by: E. A. Rezukhina, et al.
Published: (2023-03-01) -
UPTRAVI (SELEXIPAG) HAS BEEN REGISTERED IN THE RUSSIAN FEDERATION FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN ADULT PATIENTS
by: article Editorial
Published: (2019-12-01) -
Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
by: E. A. Rezukhina, et al.
Published: (2021-09-01) -
Efficacy and Safety of Selexipag Treatment in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease
by: Chebly Dagher, et al.
Published: (2025-06-01)